Click here to get full coverage on H.C. Wainwright Lifts PT on Atai Life Sciences (ATAI) to $15 From $10 - Yahoo Finance

H.C. Wainwright Lifts PT on Atai Life Sciences (ATAI) to $15 From $10  Yahoo Finance

H.C. Wainwright Lifts PT on Atai Life Sciences (ATAI) to $15 From $10 - Yahoo Finance

Click here to get full coverage on Atai and Beckley, set to merge, reveal study success for psychedelic drug - BioPharma Dive

Atai and Beckley, set to merge, reveal study success for psychedelic drug  BioPharma Dive

Atai and Beckley, set to merge, reveal study success for psychedelic drug - BioPharma Dive

Click here to get full coverage on Maxim Group Reiterates a Buy Rating on Atai Life Sciences (ATAI) With a $10 PT - Insider Monkey

Maxim Group Reiterates a Buy Rating on Atai Life Sciences (ATAI) With a $10 PT  Insider Monkey

Maxim Group Reiterates a Buy Rating on Atai Life Sciences (ATAI) With a $10 PT - Insider Monkey

Click here to get full coverage on ATAI Life Sciences Surges 15.77%: What's Behind the Sharp Intraday Move? - AInvest

ATAI Life Sciences Surges 15.77%: What's Behind the Sharp Intraday Move?  AInvest

ATAI Life Sciences Surges 15.77%: What's Behind the Sharp Intraday Move? - AInvest

Click here to get full coverage on ATAI Life Sciences stock falls after Recognify’s CIAS drug misses endpoint - Investing.com

ATAI Life Sciences stock falls after Recognify’s CIAS drug misses endpoint  Investing.com

ATAI Life Sciences stock falls after Recognify’s CIAS drug misses endpoint - Investing.com

Click here to get full coverage on Clinical Trial Reveals Promising Signals for New Schizophrenia Cognitive Drug Despite Missed Endpoint - Stock Titan

Clinical Trial Reveals Promising Signals for New Schizophrenia Cognitive Drug Despite Missed Endpoint  Stock Titan

Clinical Trial Reveals Promising Signals for New Schizophrenia Cognitive Drug Despite Missed Endpoint - Stock Titan

Click here to get full coverage on Atai's schizophrenia drug fails to improve cognition in phase 2 study - Fierce Biotech

Atai's schizophrenia drug fails to improve cognition in phase 2 study  Fierce Biotech

Atai's schizophrenia drug fails to improve cognition in phase 2 study - Fierce Biotech

Click here to get full coverage on H.C. Wainwright Lifts PT on Atai Life Sciences (ATAI) to $15 From $10 - MSN

H.C. Wainwright Lifts PT on Atai Life Sciences (ATAI) to $15 From $10  MSN

H.C. Wainwright Lifts PT on Atai Life Sciences (ATAI) to $15 From $10 - MSN

Click here to get full coverage on atai Life Sciences and Beckley Psytech Announce Positive - GlobeNewswire

atai Life Sciences and Beckley Psytech Announce Positive  GlobeNewswire

atai Life Sciences and Beckley Psytech Announce Positive - GlobeNewswire

Click here to get full coverage on atai Life Sciences Bets Big On Psychedelics For Mental Health - Finimize

atai Life Sciences Bets Big On Psychedelics For Mental Health  Finimize

atai Life Sciences Bets Big On Psychedelics For Mental Health - Finimize

Click here to get full coverage on Atai Life Sciences plans to merge with psychedelic startup Beckley Psytech - statnews.com

Atai Life Sciences plans to merge with psychedelic startup Beckley Psytech  statnews.com

Atai Life Sciences plans to merge with psychedelic startup Beckley Psytech - statnews.com

Click here to get full coverage on atai Life Sciences (ATAI) Upgraded to Strong Buy: Here's Why - Yahoo Finance

atai Life Sciences (ATAI) Upgraded to Strong Buy: Here's Why  Yahoo Finance

atai Life Sciences (ATAI) Upgraded to Strong Buy: Here's Why - Yahoo Finance

Click here to get full coverage on ATAI Life Sciences Shares Soar Following Strong Phase 2b Results for Depression Treatment - MSN

ATAI Life Sciences Shares Soar Following Strong Phase 2b Results for Depression Treatment  MSN

ATAI Life Sciences Shares Soar Following Strong Phase 2b Results for Depression Treatment - MSN

Click here to get full coverage on ATAI Life Sciences Surges 20.9%: What’s Behind the Sharp Intraday Move? - AInvest

ATAI Life Sciences Surges 20.9%: What’s Behind the Sharp Intraday Move?  AInvest

ATAI Life Sciences Surges 20.9%: What’s Behind the Sharp Intraday Move? - AInvest

Click here to get full coverage on Atai backs away from schizophrenia drug after trial failure - BioPharma Dive

Atai backs away from schizophrenia drug after trial failure  BioPharma Dive

Atai backs away from schizophrenia drug after trial failure - BioPharma Dive

Click here to get full coverage on Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year?  Yahoo Finance

Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Click here to get full coverage on ATAI Life Sciences Surges 15.77%: What’s Behind the Sharp Intraday Move? - AInvest

ATAI Life Sciences Surges 15.77%: What’s Behind the Sharp Intraday Move?  AInvest

ATAI Life Sciences Surges 15.77%: What’s Behind the Sharp Intraday Move? - AInvest

Click here to get full coverage on Atai Life Sciences schizophrenia drug fails to meet main goal in trial - MSN

Atai Life Sciences schizophrenia drug fails to meet main goal in trial  MSN

Atai Life Sciences schizophrenia drug fails to meet main goal in trial - MSN

Click here to get full coverage on ATAI Life Sciences (ATAI) Stock Plunge on Trial Failure News - Yahoo Finance

ATAI Life Sciences (ATAI) Stock Plunge on Trial Failure News  Yahoo Finance

ATAI Life Sciences (ATAI) Stock Plunge on Trial Failure News - Yahoo Finance

Click here to get full coverage on Latham & Watkins Advises atai Life Sciences on US$50 Million Private Placement Financing - Latham & Watkins LLP

Latham & Watkins Advises atai Life Sciences on US$50 Million Private Placement Financing  Latham & Watkins LLP

Latham & Watkins Advises atai Life Sciences on US$50 Million Private Placement Financing - Latham & Watkins LLP

Click here to get full coverage on H.C. Wainwright Raises Price Target on Atai Life Sciences to $15. - AInvest

H.C. Wainwright Raises Price Target on Atai Life Sciences to $15.  AInvest

H.C. Wainwright Raises Price Target on Atai Life Sciences to $15. - AInvest

Click here to get full coverage on Atai Life Sciences price target raised to $16 from $14 at Oppenheimer - TipRanks

Atai Life Sciences price target raised to $16 from $14 at Oppenheimer  TipRanks

Atai Life Sciences price target raised to $16 from $14 at Oppenheimer - TipRanks

Click here to get full coverage on 10 Best Strong Buy Penny Stocks to Buy Now - Insider Monkey

10 Best Strong Buy Penny Stocks to Buy Now  Insider Monkey

10 Best Strong Buy Penny Stocks to Buy Now - Insider Monkey

Click here to get full coverage on How does Atai Life Sciences N.V. generate profit in a changing economy - Free Trend-Following Techniques - Jammu Links News

How does Atai Life Sciences N.V. generate profit in a changing economy - Free Trend-Following Techniques  Jammu Links News

How does Atai Life Sciences N.V. generate profit in a changing economy - Free Trend-Following Techniques - Jammu Links News

Click here to get full coverage on What is ATAI company’s growth strategy - Capitalize on strong market momentum - Jammu Links News

What is ATAI company’s growth strategy - Capitalize on strong market momentum  Jammu Links News

What is ATAI company’s growth strategy - Capitalize on strong market momentum - Jammu Links News

Click here to get full coverage on Are Medical Stocks Lagging atai Life Sciences (ATAI) This Year? - Yahoo Finance

Are Medical Stocks Lagging atai Life Sciences (ATAI) This Year?  Yahoo Finance

Are Medical Stocks Lagging atai Life Sciences (ATAI) This Year? - Yahoo Finance

Click here to get full coverage on How does Atai Life Sciences N.V. compare to its industry peers - Expert Picks Review With Low Risk - Jammu Links News

How does Atai Life Sciences N.V. compare to its industry peers - Expert Picks Review With Low Risk  Jammu Links News

How does Atai Life Sciences N.V. compare to its industry peers - Expert Picks Review With Low Risk - Jammu Links News

Click here to get full coverage on Does Atai Life Sciences N.V. stock perform well during market downturns - Track top-performing stocks effortlessly - Jammu Links News

Does Atai Life Sciences N.V. stock perform well during market downturns - Track top-performing stocks effortlessly  Jammu Links News

Does Atai Life Sciences N.V. stock perform well during market downturns - Track top-performing stocks effortlessly - Jammu Links News

Click here to get full coverage on Atai Therapeutics discovers new 5-HT2A receptor partial agonists - BioWorld MedTech

Atai Therapeutics discovers new 5-HT2A receptor partial agonists  BioWorld MedTech

Atai Therapeutics discovers new 5-HT2A receptor partial agonists - BioWorld MedTech

Click here to get full coverage on Atai Life Sciences N.V. Stock Analysis and Forecast - Free Stock Market Return Analysis - Jammu Links News

Atai Life Sciences N.V. Stock Analysis and Forecast - Free Stock Market Return Analysis  Jammu Links News

Atai Life Sciences N.V. Stock Analysis and Forecast - Free Stock Market Return Analysis - Jammu Links News

Click here to get full coverage on Atai-Partnered Schizophrenia Drug Flunks Mid-Stage Trial - BioSpace

Atai-Partnered Schizophrenia Drug Flunks Mid-Stage Trial  BioSpace

Atai-Partnered Schizophrenia Drug Flunks Mid-Stage Trial - BioSpace

Click here to get full coverage on Spravato sales momentum underscores market potential for psychedelics, atai Life Sciences seen as key beneficiary - Proactive financial news

Spravato sales momentum underscores market potential for psychedelics, atai Life Sciences seen as key beneficiary  Proactive financial news

Spravato sales momentum underscores market potential for psychedelics, atai Life Sciences seen as key beneficiary - Proactive financial news

Click here to get full coverage on Stocks to Watch: Atai Life Sciences, Amrep - MarketWatch

Stocks to Watch: Atai Life Sciences, Amrep  MarketWatch

Stocks to Watch: Atai Life Sciences, Amrep - MarketWatch

Click here to get full coverage on Beckley Psytech's psychedelic reduces depression symptoms in phase 2, triggering Atai merger - Fierce Biotech

Beckley Psytech's psychedelic reduces depression symptoms in phase 2, triggering Atai merger  Fierce Biotech

Beckley Psytech's psychedelic reduces depression symptoms in phase 2, triggering Atai merger - Fierce Biotech

Click here to get full coverage on atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies - GlobeNewswire

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies  GlobeNewswire

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies - GlobeNewswire

Click here to get full coverage on ATAI Life Sciences Surges Amidst Market Uncertainty - StocksToTrade

ATAI Life Sciences Surges Amidst Market Uncertainty  StocksToTrade

ATAI Life Sciences Surges Amidst Market Uncertainty - StocksToTrade

Click here to get full coverage on atai Life Sciences Announces $50 Million Private Placement Financing - Yahoo Finance

atai Life Sciences Announces $50 Million Private Placement Financing  Yahoo Finance

atai Life Sciences Announces $50 Million Private Placement Financing - Yahoo Finance

Click here to get full coverage on ATAI Life Sciences Raises $50M to Transform Mental Health Treatment: Key Investors Back Psychedelic Innovation - Stock Titan

ATAI Life Sciences Raises $50M to Transform Mental Health Treatment: Key Investors Back Psychedelic Innovation  Stock Titan

ATAI Life Sciences Raises $50M to Transform Mental Health Treatment: Key Investors Back Psychedelic Innovation - Stock Titan

Click here to get full coverage on atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates - Yahoo Finance

atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates  Yahoo Finance

atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates - Yahoo Finance

Click here to get full coverage on Does ATAI stock perform well during market downturns - Tremendous portfolio expansion - Jammu Links News

Does ATAI stock perform well during market downturns - Tremendous portfolio expansion  Jammu Links News

Does ATAI stock perform well during market downturns - Tremendous portfolio expansion - Jammu Links News

Click here to get full coverage on Atai Life Sciences down 12% after hours on mid-stage failure of schizophrenia asset - Seeking Alpha

Atai Life Sciences down 12% after hours on mid-stage failure of schizophrenia asset  Seeking Alpha

Atai Life Sciences down 12% after hours on mid-stage failure of schizophrenia asset - Seeking Alpha

Click here to get full coverage on How volatile is Atai Life Sciences N.V. stock compared to the market - Achieve consistent profits with expert advice - Jammu Links News

How volatile is Atai Life Sciences N.V. stock compared to the market - Achieve consistent profits with expert advice  Jammu Links News

How volatile is Atai Life Sciences N.V. stock compared to the market - Achieve consistent profits with expert advice - Jammu Links News

Click here to get full coverage on ATAI Life Sciences: Revised Price Target to $15 Despite Setback in Schizophrenia Treatment Trial - AInvest

ATAI Life Sciences: Revised Price Target to $15 Despite Setback in Schizophrenia Treatment Trial  AInvest

ATAI Life Sciences: Revised Price Target to $15 Despite Setback in Schizophrenia Treatment Trial - AInvest

Click here to get full coverage on What are analysts’ price targets for Atai Life Sciences N.V. in the next 12 months - Boost your returns with professional guidance - Jammu Links News

What are analysts’ price targets for Atai Life Sciences N.V. in the next 12 months - Boost your returns with professional guidance  Jammu Links News

What are analysts’ price targets for Atai Life Sciences N.V. in the next 12 months - Boost your returns with professional guidance - Jammu Links News

Click here to get full coverage on What are analysts’ price targets for Atai Life Sciences N.V. in the next 12 months - Free Stock Market Forecast Reports - Jammu Links News

What are analysts’ price targets for Atai Life Sciences N.V. in the next 12 months - Free Stock Market Forecast Reports  Jammu Links News

What are analysts’ price targets for Atai Life Sciences N.V. in the next 12 months - Free Stock Market Forecast Reports - Jammu Links News

Click here to get full coverage on Latham Watkins Advises atai Life Sciences in Strategic Combination With Beckley Psytech Limited - Latham & Watkins LLP

Latham Watkins Advises atai Life Sciences in Strategic Combination With Beckley Psytech Limited  Latham & Watkins LLP

Latham Watkins Advises atai Life Sciences in Strategic Combination With Beckley Psytech Limited - Latham & Watkins LLP

Click here to get full coverage on Why is ATAI stock attracting strong analyst attention - Expert guidance for superior capital growth - Jammu Links News

Why is ATAI stock attracting strong analyst attention - Expert guidance for superior capital growth  Jammu Links News

Why is ATAI stock attracting strong analyst attention - Expert guidance for superior capital growth - Jammu Links News

Click here to get full coverage on Is atai Life Sciences (ATAI) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Is atai Life Sciences (ATAI) Outperforming Other Medical Stocks This Year?  Yahoo Finance

Is atai Life Sciences (ATAI) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Click here to get full coverage on atai Life Sciences stock price target raised to $12 by Canaccord on positive trial data - Investing.com

atai Life Sciences stock price target raised to $12 by Canaccord on positive trial data  Investing.com

atai Life Sciences stock price target raised to $12 by Canaccord on positive trial data - Investing.com

Click here to get full coverage on ATAI Life Sciences: HC Wainwright maintains Buy, raises PT to $15 from $10. - AInvest

ATAI Life Sciences: HC Wainwright maintains Buy, raises PT to $15 from $10.  AInvest

ATAI Life Sciences: HC Wainwright maintains Buy, raises PT to $15 from $10. - AInvest

Click here to get full coverage on Canaccord Genuity Lifts Atai Life Sciences N.V. (ATAI)’s Price Target To $12, Maintains Buy Rating - Insider Monkey

Canaccord Genuity Lifts Atai Life Sciences N.V. (ATAI)’s Price Target To $12, Maintains Buy Rating  Insider Monkey

Canaccord Genuity Lifts Atai Life Sciences N.V. (ATAI)’s Price Target To $12, Maintains Buy Rating - Insider Monkey

Click here to get full coverage on Atai Life Sciences To Raise $50 Mln Via Private Placement To Fund Clinical Programs; Stock Up - Nasdaq

Atai Life Sciences To Raise $50 Mln Via Private Placement To Fund Clinical Programs; Stock Up  Nasdaq

Atai Life Sciences To Raise $50 Mln Via Private Placement To Fund Clinical Programs; Stock Up - Nasdaq

Click here to get full coverage on Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus (ATAI) - Seeking Alpha

Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus (ATAI)  Seeking Alpha

Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus (ATAI) - Seeking Alpha

Click here to get full coverage on Breaking: atai Moves to Acquire Beckley, If Phase 2b 5-MeO-DMT Data Delivers - Psychedelic Alpha

Breaking: atai Moves to Acquire Beckley, If Phase 2b 5-MeO-DMT Data Delivers  Psychedelic Alpha

Breaking: atai Moves to Acquire Beckley, If Phase 2b 5-MeO-DMT Data Delivers - Psychedelic Alpha

Click here to get full coverage on Why Did ATAI Life Sciences Soar 11.71% Despite Trial Setback? - AInvest

Why Did ATAI Life Sciences Soar 11.71% Despite Trial Setback?  AInvest

Why Did ATAI Life Sciences Soar 11.71% Despite Trial Setback? - AInvest

Click here to get full coverage on Study win sets up atai, Beckley Psytech's psychedelic depression therapy for late-stage - FirstWord Pharma

Study win sets up atai, Beckley Psytech's psychedelic depression therapy for late-stage  FirstWord Pharma

Study win sets up atai, Beckley Psytech's psychedelic depression therapy for late-stage - FirstWord Pharma

Click here to get full coverage on New Analyst Forecast: $ATAI Given $11.0 Price Target - Quiver Quantitative

New Analyst Forecast: $ATAI Given $11.0 Price Target  Quiver Quantitative

New Analyst Forecast: $ATAI Given $11.0 Price Target - Quiver Quantitative

Click here to get full coverage on Why Did ATAI Life Sciences Plunge 10.08%? - AInvest

Why Did ATAI Life Sciences Plunge 10.08%?  AInvest

Why Did ATAI Life Sciences Plunge 10.08%? - AInvest

Click here to get full coverage on ATAI Life Sciences: Strategic Positioning and Diversified Portfolio Drive Buy Rating - TipRanks

ATAI Life Sciences: Strategic Positioning and Diversified Portfolio Drive Buy Rating  TipRanks

ATAI Life Sciences: Strategic Positioning and Diversified Portfolio Drive Buy Rating - TipRanks

Click here to get full coverage on This Atai Life Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Benzinga

This Atai Life Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday  Benzinga

This Atai Life Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Benzinga

Click here to get full coverage on atai Life Sciences (ATAI) Upgraded to Strong Buy: Here's Why - Nasdaq

atai Life Sciences (ATAI) Upgraded to Strong Buy: Here's Why  Nasdaq

atai Life Sciences (ATAI) Upgraded to Strong Buy: Here's Why - Nasdaq

Click here to get full coverage on Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. (ATAI) is a Great Choice - Nasdaq

Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. (ATAI) is a Great Choice  Nasdaq

Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. (ATAI) is a Great Choice - Nasdaq

Click here to get full coverage on Major Psychedelic Merger: atai and Beckley Join Forces in $390M Deal to Transform Mental Health Treatment - Stock Titan

Major Psychedelic Merger: atai and Beckley Join Forces in $390M Deal to Transform Mental Health Treatment  Stock Titan

Major Psychedelic Merger: atai and Beckley Join Forces in $390M Deal to Transform Mental Health Treatment - Stock Titan

Click here to get full coverage on How many analysts rate ATAI as a “Buy” - Unlock your trading potential today - Jammu Links News

How many analysts rate ATAI as a “Buy” - Unlock your trading potential today  Jammu Links News

How many analysts rate ATAI as a “Buy” - Unlock your trading potential today - Jammu Links News

Click here to get full coverage on Oppenheimer initiates coverage on ATAI Life Sciences with Outperform rating, $14 PT. - AInvest

Oppenheimer initiates coverage on ATAI Life Sciences with Outperform rating, $14 PT.  AInvest

Oppenheimer initiates coverage on ATAI Life Sciences with Outperform rating, $14 PT. - AInvest

Click here to get full coverage on Can Psychedelics Break Through in Depression? Recent Readouts Leave Investors Wanting More - BioSpace

Can Psychedelics Break Through in Depression? Recent Readouts Leave Investors Wanting More  BioSpace

Can Psychedelics Break Through in Depression? Recent Readouts Leave Investors Wanting More - BioSpace

Click here to get full coverage on atai Life Sciences: A Leading Candidate in the Treatment-Resistant Depression Market with Intranasal 5-MeO-DMT BPL-003 - AInvest

atai Life Sciences: A Leading Candidate in the Treatment-Resistant Depression Market with Intranasal 5-MeO-DMT BPL-003  AInvest

ATAI Life Sciences BV (ATAI)

Price Chart

Key Statistics

Technicals

About ATAI

Latest News

H.C. Wainwright Lifts PT on Atai Life Sciences (ATAI) to $15 From $10 - Yahoo Finance

Atai and Beckley, set to merge, reveal study success for psychedelic drug - BioPharma Dive

Maxim Group Reiterates a Buy Rating on Atai Life Sciences (ATAI) With a $10 PT - Insider Monkey

Advanced Charts

Top Gainers

Top Losers